Eli Lilly said on Tuesday it cut the price for vials of its weight-loss drug Zepbound by $50 or more and expanded the range of doses sold online to try to stave off competition from compounding pharmacies and rival Novo Nordisk .

Eli Lilly (LLY) and Novo Nordisk (NVO) to dominate as TD Cowen lifts 2030 sales forecast for GLP-1 class of obesity/ diabetes drugs by 38% to $139B. REad more here.

Novo Nordisk said Wednesday it will sell Wegovy for $499 a month in cash to patients who can’t get the blockbuster weight-loss drug through insurance, a bid to reach consumers who can’t afford the $1,

Revenues in the biopharma industry continued to boom in the fourth quarter of last year, following a pattern seen increasingly throughout 2024. | Revenues in the biopharma industry continued to boom in the fourth quarter of last year,

Novo Nordisk is cutting prices on weight-loss drug Wegovy, a week after Eli Lilly did the same for rival Zepbound.

Novo Nordisk will explore how GLP-1 drugs could help patients struggling with addiction, its head of development Martin Holst Lange told an online press conference on Thursday. GLP-1 drugs on the market include Novo Nordisk's diabetes drug Ozempic,

Telehealth firms Teladoc Health and LifeMD said on Thursday they have signed an agreement with Eli Lilly's direct-to-consumer website LillyDirect pharmacy partner, Gifthealth, to offer patients the weight-loss drug,

Novo Nordisk will slash the price of its blockbuster weight-loss drug Wegovy for cash-paying patients, after American rival Eli Lilly discounted some of its Zepbound injections last week. The Danish drugmaker will sell Wegovy directly to patients through its own online pharmacy.

As a federal court in Texas hears a case pitting the FDA versus compounders who want to continue to manufacture cheaper knockoff versions of popular weight loss drugs, Novo Nordisk will not have to | A federal district court in Texas will allow Novo Nordisk to intervene in a lawsuit pitting compounders against the FDA.

Novo Nordisk said it will offer all doses of Wegovy for $499 a month to patients paying cash, a bid to reach consumers who can’t get the blockbuster drug through insurance.